BiotechTubeBiotechTube
Home/Valneva SE/James (Jim) F. Cummings
J(

James (Jim) F. Cummings

Executive Vice President, General Counsel

Valneva SE

Roles

Executive Vice President, General CounselatValneva SE
Chief Science OfficeratZomedica Pharmaceuticals

Therapeutic Areas

Infectious DiseasesTravel Medicine

Valneva SE Pipeline

DrugIndicationPhase
IXCHIQ® (VLA1553)Chikungunya virus disease (prevention)Approved
IXIARO®/JESPECT®Japanese Encephalitis (prevention)Approved
VLA15Lyme Borreliosis (prevention)Phase 3
VLA1553 (Pediatric)Chikungunya (prevention) in pediatric populationPhase 3
VLA2111Chikungunya (prevention)Phase 1
VLA1601Zika virus disease (prevention)Preclinical

Leadership Team at Valneva SE

TL
Thomas Lingelbach
Chief Executive Officer (CEO) and Director of Valneva Austria GmbH
PB
Peter Bühler
Chief Financial Officer (CFO)
JC
Juan Carlos Jaramillo, M.D.
Chief Medical Officer (CMO)
FJ
Frédéric Jacotot
Executive Vice President, Corporate Strategy
FG
Franck Grimaud
Executive Vice President, Chief Business Officer
HB
Hervé Brailly, Ph.D.
Chairman of the Supervisory Board
WB
Wolfgang Bender, Ph.D., MBA
Member of the Supervisory Board
MM
Muriel Marchand
Member of the Supervisory Board
S(
Svetlana (Lana) Skibo
Member of the Supervisory Board
YG
Yvonne Greenstreet, MBChB
Member of the Supervisory Board
View full Valneva SE profile